<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01781390</url>
  </required_header>
  <id_info>
    <org_study_id>ANG.AMI-IC001</org_study_id>
    <nct_id>NCT01781390</nct_id>
  </id_info>
  <brief_title>Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction</brief_title>
  <acronym>AMICI</acronym>
  <official_title>A Prospective, DB, Randomized, Placebo-controlled Clinical Trial of IC Infusion of Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind, randomized, placebo controlled study that will enroll 105 subjects&#xD;
      with de novo anterior myocardial infarction due to a lesion of the left anterior descending&#xD;
      coronary artery undergoing PCI. Eligible subjects will be enrolled and undergo&#xD;
      revascularization of the culprit LAD followed by an intracoronary (IC) delivery of the&#xD;
      assigned treatment, infused into the stented culprit artery. The study will determine the&#xD;
      safety and feasibility of the IC infusion of investigational MPCs in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, double-blind, randomized, placebo-controlled study that will enroll&#xD;
      approximately 105 subjects with de novo anterior STEMI due to a lesion involving LAD coronary&#xD;
      artery who undergo primary PCI at approximately 25 clinical study sites.&#xD;
&#xD;
      This study will compare two doses of MPCs and a placebo control group. Study subjects will be&#xD;
      randomly assigned in 1:1:1 fashion to receive either 12.5 Million or 25 Million MPCs or&#xD;
      placebo (saline). Each group will have approximately 35 subjects.&#xD;
&#xD;
      Potential subjects will be approached by a site investigator prior to PCI and must sign an&#xD;
      informed consent form before initiation of the cardiac catheterization procedure in order to&#xD;
      participate in this trial. Following successful and uneventful PCI and stenting of the&#xD;
      culprit LAD lesion, the subjects will be randomized. The randomization and treatment&#xD;
      assignment will be obtained from an interactive voice-response system (IVRS/interactive web&#xD;
      response system (IWRS)). The following stratification for duration of cardiac ischemia will&#xD;
      be performed to ensure balanced randomization across the treatment groups:&#xD;
&#xD;
        -  ≤2 hours&#xD;
&#xD;
        -  &gt;2 hours to ≤6 hours&#xD;
&#xD;
        -  &gt;6 to ≤12 hours Eligible subjects will receive intracoronary delivery of the assigned&#xD;
           treatment infused via a microcatheter into the stented culprit artery.&#xD;
&#xD;
      After approximately 50% of the intracoronary infusion of investigational agent has been&#xD;
      completed, an angiographic determination of coronary flow will be performed. The following&#xD;
      guidelines will be used to determine if the remaining investigational agent should be&#xD;
      infused:&#xD;
&#xD;
      The study infusion should be continued if either TIMI 2 or TIMI 3 flow is present in the&#xD;
      absence of ALL of the following;&#xD;
&#xD;
        -  Sustained hypotension not responsive to fluid administration;&#xD;
&#xD;
        -  Clinical signs/symptoms indicating an acute cerebrovascular event;&#xD;
&#xD;
        -  Re-elevation of ST-segments if previously resolved with PCI;&#xD;
&#xD;
        -  Onset of the subject's symptoms of myocardial ischemia unresponsive to appropriate&#xD;
           interventions;&#xD;
&#xD;
        -  Two episodes of sustained ventricular tachycardia (VT)/ventricular fibrillation (VF)&#xD;
           requiring cardioversion (infusion can continue if a single episode of sustained VT/VF&#xD;
           requiring cardioversion occurred).&#xD;
&#xD;
      If for any reason, the site investigator withdraws a randomized subject prior to infusion of&#xD;
      the investigational agent, the reason for early termination and data from the screening visit&#xD;
      will be entered into the eCRF by the study site. The subject will not remain in the study. If&#xD;
      for any reason, a subject's study infusion is halted due to safety considerations, the&#xD;
      subject will remain in the study. A subject who prematurely withdraws from the study, post-&#xD;
      study infusion will remain in the study.&#xD;
&#xD;
      Evaluation for safety will be performed for up to 24 months post infusion. Subjects will&#xD;
      undergo cardiac imaging (using cMRI and 2D-echocardiography), Holter monitoring, clinical&#xD;
      evaluations, and laboratory testing. Clinical evaluations and safety laboratory testing will&#xD;
      be performed post infusion of investigational agent as outlined in the study protocol.&#xD;
&#xD;
      Subjects enrolled in Sweden who consent for additional safety follow-up will be followed for&#xD;
      safety assessments at 36, 48, and 60 months post-infusion of investigational agent.&#xD;
&#xD;
      An independent Data Monitoring Safety Board (DSMB) will review all relevant acute&#xD;
      peri-procedural data, serious adverse events (SAE), other adverse events (AE), and efficacy&#xD;
      data (if requested) periodically until subject enrolment is closed&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2012</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Actual">July 17, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint is the change in left ventricular (LV) end-systolic volume (LVESV) as assessed by cardiac MRI from baseline to 6 months post investigational agent infusion</measure>
    <time_frame>6 months</time_frame>
    <description>The objective is to assess LV chamber remodeling at 6 months post index STEMI.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>12.5M Mesenchymal Precursor Cells (MPC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.5M Mesenchymal Precursor Cell (MPC) administered via IC infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25M Mesenchymal Precursor Cells (MPC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25M Mesenchymal Precursor Cell (MPC) administered via IC infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo via IC infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>12.5 M Mesenchymal Precursor Cells (MPC)</intervention_name>
    <description>MPCs</description>
    <arm_group_label>12.5M Mesenchymal Precursor Cells (MPC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>25M Mesenchymal Precursor Cells (MPC)</intervention_name>
    <description>MPC</description>
    <arm_group_label>25M Mesenchymal Precursor Cells (MPC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Clinical symptoms consistent with AMI (pain, etc.) for a maximum of 12 hours from&#xD;
             onset of symptoms to percutaneous coronary intervention (PCI)&#xD;
&#xD;
          -  De Novo anterior Acute Myocardial Infarct (AMI)&#xD;
&#xD;
          -  Successful revascularization of the culprit lesion&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior AMI, known cardiomyopathy, or hospital admission for heart failure (HF)&#xD;
&#xD;
          -  Significant valvular disease&#xD;
&#xD;
          -  Need for other interventional or surgical procedure to treat heart disease (planned or&#xD;
             scheduled)&#xD;
&#xD;
          -  Cardiogenic shock or hemodynamic instability within 24 hours of randomization&#xD;
&#xD;
          -  Prior PCI to LAD&#xD;
&#xD;
          -  Pacemaker, ICD (Implantable Cardioverter Defibrillator), or any other&#xD;
             contra-indication for cardiac MRI&#xD;
&#xD;
          -  Prior or current participation in any stem cell study or any other investigational&#xD;
             trial in the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Grossman, DO</last_name>
    <role>Study Director</role>
    <affiliation>Mesoblast, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Henry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedar-Sinai Heart Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2013</study_first_posted>
  <disposition_first_submitted>February 24, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>February 24, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 26, 2019</disposition_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>STEMI</keyword>
  <keyword>Heart Attack</keyword>
  <keyword>AMI</keyword>
  <keyword>Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

